Abstract
The connection between antiresorptive medications, like bisphosphonates and denosumab, and osteonecrosis of the jaw has been well studied in the literature. A 10-year retrospective case-control analysis of the patient population at the University of Southern California, Herman Ostrow School of Dentistry, found a robust population of patients of record with a history of bisphosphonate or denosumab use and a significant subset of those patients had medication-related osteonecrosis of the jaw (MRONJ). This study explores the demographic and clinical factors associated with risk for MRONJ in patients taking antiresorptive medications. Multivariate analysis indicated that patients at greatest risk were over 60 years of age, female sex, Asian race, had cancer as a comorbidity, had a history of tooth extraction, and also patients on long-term antiresorptive pharmacotherapy. The findings of this study should help guide clinicians to identify patients at high risk for MRONJ, and thus patients that would benefit from risk reduction and prevention protocols.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
